VivoSeq
Other

Prosthetic-Joint Infection

1

Pipeline Programs↗

9

Active Trials↗

3

Companies Involved↗

Prosthetic-joint Infection is an early-stage landscape with 1 program across 3 companies. The most active players are Eli Lilly, Adaptive Phage Therapeutics, Inc., Phaxiam Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

56/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

PreclinicalA

Adaptive Phage Therapeutics, Inc.

0 programs

PreclinicalP

Phaxiam Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

PLG0206

Peptilogics

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

24

clinical trials

Unknown status6 · 25%
Completed5 · 21%
Recruiting3 · 13%
Withdrawn3 · 13%
Not yet recruiting3 · 13%
Active, not recruiting2 · 8%
Other2 · 8%

Clinical Trials

Trial Activity

24 trials

Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
Recruiting·TTrellis Bioscience LLC·Phase 2·NCT06621251·60 enrolled
Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
Recruiting·LLeiden University Medical Center·Phase 4·NCT06172010·316 enrolled
RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)
Recruiting·PPeptilogics·Preclinical·NCT07214311·240 enrolled
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
Active, not recruiting·UUniversity of Calgary·Phase 1/2·NCT06456424·1 enrolled
Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection
Active, not recruiting·UUniversity of Calgary·Phase 1/2·NCT06814756·1 enrolled
Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.
Not yet recruiting·PPhaxiam Therapeutics·Phase 2·NCT06605651·100 enrolled
Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection
Not yet recruiting·UUniversity of Calgary·Phase 1/2·NCT07461337·1 enrolled
Evaluating the Use of Antibiotic-Coated Braided Sutures in Debridement, Antibiotic, and Implant Retention (DAIR) Procedures
Not yet recruiting·UUniversity of Miami·Preclinical·NCT07322289·142 enrolled
Probiotics in the Prevention of Recurrent Prosthetic Joint Infection of the Hip and Knee
Enrolling by invitation·—·Phase 4·NCT06636669·152 enrolled
The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures
Completed·PParc de Salut Mar·N/A·NCT02413034·28 enrolled
Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal
Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 4·NCT03746327·30 enrolled
Heraeus MicroDTTect Lyon Pilot Studyprosthetic Joint Infections (PJIs)
Completed·HHospices Civils de Lyon·N/A·NCT04371068·20 enrolled
Tedizolid Prolonged Treatment for Prosthetic Joint Infections
Completed·TTourcoing Hospital·N/A·NCT03378427·35 enrolled
Study to Evaluate Safety and Activity of TRL1068 in Prosthetic Joint Infections
Completed·TTrellis Bioscience LLC·Phase 1·NCT04763759·15 enrolled
Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection
Terminated·AArrevus Inc.·Phase 2·NCT01756924·14 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)